7-allyloxy-2,2-dimethyl-chroman-4-one | 100883-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-allyloxy-2,2-dimethyl-chroman-4-one
• 英文别名: 7-allyloxy-2,2-dimethyl-4-oxochroman；2,2-dimethyl-7-prop-2-enoxy-3H-chromen-4-one
• CAS: 100883-69-0
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: VNGUHTNKUKMDLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-allyloxy-2,2-dimethyl-chroman-4-one 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 13.0h， 生成 2,2-dimethyl-7-hydroxy-8-propylchromanone
  参考文献：
  名称：

  Patonay, Tamas; Levai, Albert; Hegedus Laszlo, Bulletin de la Societe Chimique de France, 1997, vol. 134, # 7, p. 653 - 668

  摘要：

  DOI：
• 作为产物：
  描述：

  间苯二酚 在 potassium carbonate 、 potassium iodide 、 zinc(II) chloride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 7-allyloxy-2,2-dimethyl-chroman-4-one
  参考文献：
  名称：

  Timar, Tibor; Hosztafi, Sandor; Jaszberenyi, J. Csaba, Acta Chimica Hungarica, 1988, vol. 125, # 2, p. 303 - 312

  摘要：

  DOI：

文献信息

• Indole derivative having piperidine ring
  申请人：Suzuki Yuichi

  公开号：US20050256103A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

  本发明涉及以下公式所代表的化合物，其药学上可接受的盐，或其作为药物的用途： 其中R1和R2是相邻的取代基，与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物，该基可能被1至4个取代基所取代，所述取代基选自（1）氧代基，（2）羟基等；R3代表氢原子或类似物；R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状，特别是涉及尿液储存的症状的药剂，该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
• Indole Derivative Having Piperidine Ring
  申请人：Suzuki Yuichi

  公开号：US20070219179A1

  公开（公告）日：2007-09-20

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.

  本发明涉及一种化合物，其表示为以下公式，其药理学上可接受的盐或其用途作为药物：其中R1和R2是相邻的取代基，并与它们附着的两个碳原子一起形成一个5-至7-成员的非芳香族碳环基团或类似物，该基团可以被1至4个取代基所取代，所述取代基包括(1)氧代基、(2)羟基等；R3表示氢原子或类似物；R6表示氢原子或类似物。该化合物具有优越的与5-HT1A受体结合的强度和对受体的拮抗作用，并可用作治疗或预防下尿路症状，特别是涉及尿液储存的症状的药剂。
• Crystal of Indole Derivative Having Piperidine Ring and Process for Production Thereof
  申请人：Sakaguchi Takahisa

  公开号：US20080227815A1

  公开（公告）日：2008-09-18

  A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13 C solid NMR spectrum.

  这是一种1-[1-[2-(7-甲氧基-2,2-二甲基-4-氧代色满-8-基)-乙基]哌啶-4-基]-N-甲基-1H-吲哚-6-羧酰胺富马酸盐晶体，在13C固态NMR光谱中，其化学位移峰大约为124.0 ppm和26.8 ppm。
• INDOLE DERIVATIVES HAVING PIPERIDINE RINGS
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1757599A1

  公开（公告）日：2007-02-28

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.

  本发明涉及下式所代表的化合物、其药理学上可接受的盐，或其作为药物的用途： 其中 R1 和 R2 是彼此相邻的取代基，并与它们各自连接的两个碳原子一起构成 5 至 7 元的非芳香族碳环基团或类似基团，该基团可被 1 至 4 个选自(1)氧代基团、(2)羟基和类似基团的取代基取代；R3 代表氢原子或类似基团；R6 代表氢原子或类似基团。该化合物与 5-HT1A 受体的结合强度较高，对受体有拮抗作用，可作为治疗或预防下尿路症状，特别是储尿症状的药物。
• CRYSTAL OF INDOLE DERIVATIVE HAVING PIPERIDINE RING AND PROCESS FOR PRODUCTION THEREOF
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1880994A1

  公开（公告）日：2008-01-23

  A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13C solid NMR spectrum.

  1-[1-[2-(7-甲氧基-2,2-二甲基-4-氧代苯并二氢吡喃-8-基)-乙基]哌啶-4-基]-N-甲基-1H-吲哚-6-甲酰胺富马酸盐晶体，其 13C 固体核磁共振谱中的化学位移峰分别为约 124.0 ppm 和约 26.8 ppm。